Immutep (IMMP) announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha in combination with radiotherapy plus KEYTRUDA in the neoadjuvant setting for patients with resectable soft tissue sarcoma, STS. The Phase II trial conducted by the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue